相关实验视频

Updated: Jul 18, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

在急性髓性白血病患者中预测治疗反应的有效预后模型

Maria A Kolesnikova¹, Aleksandra V Sen'kova², Tatiana I Pospelova³

¹City Hematology Center, Novosibirsk 630051, Russia.

Journal of personalized medicine

|August 25, 2023

概括

一个新的预后尺度改善了急性髓性白血病 (AML) 风险分层. 这种尺度预测了患者对化疗的反应和整体存活率,有助于新诊断的AML的治疗决策.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

急性髓性白血病 (AML) 是一种严重的血液癌症,存活率较低.
由于患者和瘤因素,预测AML的治疗反应具有挑战性.
化疗耐药性是改善AML患者治疗结果的一个主要障碍.

研究的目的:

开发一种新的预后尺度,用于AML患者的风险分层.
评估尺度能够预测治疗反应和整体存活率的能力.
确定影响AML患者结果的关键因素.

主要方法:

开发了一个预后尺度,包括体外药物敏感性,MDR1 mRNA/P-糖蛋白表达,瘤起源,细胞遗传学和免疫表型.
分析了接受密集或非密集诱导治疗的53名新诊断的AML患者.
使用相关性,ROC和Cox回归分析进行验证.

主要成果:

开发的预后尺度有效地根据风险对AML患者进行分层.
使用新规模的风险分层与治疗反应有显著的相关性.
预后尺度是新诊断的AML的整体存活率的独立预测指标.

结论:

新的预后尺度为AML患者提供了更好的风险分层.
这种工具可以帮助选择最佳的治疗策略和预测患者的结果.
结合药物敏感性和分子标记物可以提高AML预后的准确性.

关键词:

急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.药物耐药性耐药性药物耐药性风险分层的风险分层.治疗反应治疗反应的治疗.

更多相关视频

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...